ALEXIS Biochemicals: Monoclonal Antibody to Cyclosporin A (CSZ.22)

You are here: Product Lines > Natural Products / Antibiotics > Antibiotics > Antibiotics - Nitric Oxide Pathway Modulators

ALX-380-001

Revised 18-Nov-08

Troleandomycin
SYNONYMS	Oleandomycin triacetate ester
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - Nitric Oxide Pathway Modulators

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-001-G001		1 g	55.00 USD

Product Specification

FORMULA:	C₄₁H₆₇NO₁₅
MW:	814.0
CAS NUMBER:	2751-09-9
MERCK INDEX:	14: 9770
SOURCE/HOST:	Semisynthetic from oleandomycin.
PURITY:	≥98% (TLC)
APPEARANCE:	White to off-white solid.
SOLUBILITY:	Soluble in DMSO (50mg/ml), 100% ethanol (25mg/ml) or methanol.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	+20°C
USE/STABILITY:	Solutions are stable for up to 3 months when stored at -20 °C.
HAZARD:	TOXIC.

Product Description

Induces microsomal enzymes and produces an inactive cytochrome P450 Fe(II)-metabolite complex. Inhibits cytochrome P450 mediated nitric oxide (NO) release from N^G-hydroxy-L-arginine (Prod. No. ALX-106-004). Used as adjunctive therapy for the treatment of with corticosteroid-dependent asthma.

Product Specific Literature References

Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleandomycin in humans: D. Pessayre, et al.; Biochem. Pharmacol. 31, 1699 (1982) Abstract
Effects of macrolide antibiotics on drug metabolism in rats and in humans: D. Pessayre; Int. J. Clin. Pharmacol. Res. 3, 449 (1983), Review Abstract
Methylprednisolone and troleandomycin in treatment of steroid-dependent asthmatic children: R.W. Eitches, et al.; Am. J. Dis. Child. 139, 264 (1985) Abstract
Cytochrome P450 catalyzes the oxidation of N omega-hydroxy-L-arginine by NADPH and O2 to nitric oxide and citrulline: J.-L. Boucher, et al.; BBRC 187, 880 (1992) Abstract
Immunomodulatory activity and effectiveness of macrolides in chronic airway disease: B.K. Rubin & M.O. Henke; Chest 125, 70S (2004), Review Abstract

Further Categories Containing This Product:

Cytochrome P450 [CYP450] / Related Products • Antibiotics - Immunomodulators

ALX-380-002

Revised 03-Apr-08

Cyclosporin A
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - Immunomodulators

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-002-M100		100 mg	46.00 USD
ALX-380-002-5100		5x100 mg	190.00 USD
ALX-380-002-G001		1 g	290.00 USD
ALX-380-002-5001		5x1 g	1'150.00 USD

Product Specification

FORMULA:	C₆₂H₁₁₁N₁₁O₁₂
MW:	1202.6
CAS NUMBER:	59865-13-3
MERCK INDEX:	14: 2752
RTECS:	GZ4120000
SOURCE/HOST:	Isolated from Fusarium solani.
PURITY:	≥99% (Assay)
APPEARANCE:	White to off-white powder.
SOLUBILITY:	Soluble in methanol, 100% ethanol, acetone or petroleum ether; insoluble in water.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	+4°C
HAZARD:	MAY BE TERATOGENIC. TOXIC. MAY BE CARCINOGENIC.

Product Description

Antibiotic. Potent immunosuppressor. Widely used after organ transplantation. Binds to cytosolic proteins of the cyclophilin family. Cyclosporin A-cyclophilin complexes block protein phosphatase 2B (PP2B; calcineurin), a key enzyme in T cell activation. As a result of the calcineurin inhibition, cyclosporine A blocks various cellular processes such as activation of T cells and expression of several lymphokines (especially IL-2). Inhibits cytochrome c release from mitochondria. Inhibits nitric oxide (NO) synthesis.

Product Specific Literature References

Cyclosporin A and C-New metabolites from Trichodermapolysporum (Link ex Pers.) Rifai: Dreyfuss M., et al.; Europ. J. appl. Microbiol. 3, 125 (1976)
Immunosuppression for organ grafting - observations on cyclosporin A: R. Y. Calne; Immunol. Rev. 46, 113 (1976), Review Abstract
Immunological actions of cyclosporin A in rheumatoid arthritis: D. Yocum; Br. J. Rheumatol. 32, 38 (1993), Review Abstract
Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury: A.P. Halestrap, et al; Mol. Cell. Biochem. 174, 167 (1997), Review Abstract
New aspects of cyclosporin a mode of action: from gene silencing to gene up-regulation: L. Mascarell & P. Truffa-Bachi; Mini Rev. Med. Chem. 3, 205 (2003), Review Abstract
Rationale for T cell inhibition by cyclosporin A in major autoimmune diseases: G.F. Ferraccioli, et al.; Ann. N. Y. Acad. Sci. 1051, 658 (2005), Review Abstract

Further Categories Containing This Product:

MPTP [Mitochondrial Transition Pore] / Related Products • Antibiotics - Nitric Oxide Pathway Modulators • Antibiotics - Apoptosis Inducers & Inhibitors • Non-apoptotic Cell Death / Necrosis

ALX-380-010

Revised 08-Oct-08

Streptozotocin
SYNONYMS	Streptozocin 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose STZ
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - Nitric Oxide Pathway Modulators

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-010-M100		100 mg	25.00 USD
ALX-380-010-5100		5x100 mg	65.00 USD
ALX-380-010-G001		1 g	74.00 USD

Product Specification

FORMULA:	C₈H₁₅N₃O₇
MW:	265.2
CAS NUMBER:	18883-66-4
MERCK INDEX:	14: 8832
RTECS:	LZ5775000
PURITY:	≥97%
APPEARANCE:	White to pale yellow solid.
SOLUBILITY:	Soluble in water or 100% ethanol.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
HAZARD:	TOXIC. MAY BE CARCINOGENIC.

Product Description

Widely used diabetes inducer in rodents. Inhibition of β-cell O-GlcNAcase by streptozotocin is the mechanism that accounts for its diabetogenic toxicity. N-nitroso-containing antibiotic, acting as a nitric oxide (NO) donor. Potent methylating agent for DNA.

Product Specific Literature References

Studies on the diabetogenic action of streptozotocin: N. Rakieten, et al.; Cancer Chemother. Rep. 29, 91 (1963)
The structure of streptozotocin: R.R. Herr, et al.; JACS 89, 4808 (1967) Abstract
Alkylation of DNA in rat tissues following administration of streptozotocin: R.A. Bennett & A.E. Pegg; Cancer Res. 41, 2786 (1981) Abstract
Streptozotocin: a nitric oxide carrying molecule and its effect on vasodilation: G. Thomas & P. Ramwell; Eur. J. Pharmacol. 161, 279 (1989) Abstract
NO- and NO2-carrying molecules potentiate photorelaxation in rat trachea and aorta: K.C. Chang, et al.; BBRC 191, 509 (1993) Abstract
Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets: J. Turk, et al.; BBRC 197, 1458 (1993) Abstract
Nitric oxide generation from streptozotocin: N.S. Kwon, et al.; FASEB J. 8, 529 (1994) Abstract
Nitric oxide generation during cellular metabolization of the diabetogenic N-methyl-N-nitroso-urea streptozotozin contributes to islet cell DNA damage: K.-D. Kroncke, et al.; Biol. Chem. Hoppe Seyler 376, 179 (1995) Abstract
The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas: T. Szkudelski; Physiol. Res. 50, 537 (2001), (Review) Abstract
Genotoxicity of streptozotocin: A.D. Bolzan & M.S. Bianchi; Mutat. Res. 512, 121 (2002), (Review) Abstract
Streptozotocin induces G2 arrest in skeletal muscle myoblasts and impairs muscle growth in vivo: A.P. Johnston, et al.; Am. J. Physiol. Cell Physiol. 292, C1033 (2007) Abstract

Further Categories Containing This Product:

Obesity & Diabetes Other Products • Nitric Oxide Donors • Antitumor Antibiotics

ALX-380-011

Revised 01-Oct-07

Fusidic acid . sodium salt
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - Nitric Oxide Pathway Modulators

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-011-M050		50 mg	15.00 USD

Product Specification

FORMULA:	C₃₁H₄₇O₆ . Na
MW:	515.7 . 23.0
CAS NUMBER:	751-94-0
MERCK INDEX:	14: 4317
PURITY:	≥98%
APPEARANCE:	White to off-white solid.
SOLUBILITY:	Soluble in water.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	+4°C
HAZARD:	TOXIC.

Product Description

Antibiotic which suppresses nitric oxide (NO) toxicity in pancreatic islet cells. Inhibits protein synthesis by inhibition of elongation factor G at the level of the ribosome.

Product Specific Literature References

Fusidic acid: a new antibiotic: W.O. Godtfredsen, et al.; Nature 193, 987 (1962) Abstract
Mechanism of protein synthesis inhibition by fusidic acid and related antibiotics: N. Tanaka, et al.; BBRC 30, 278 (1968) Abstract
On the Mode of Action of Fusidic Acid: C.L. Harvey, et al.; Biochemistry 5, 3320 (1969)
Fusidic acid suppresses nitric oxide toxicity in pancreatic islet cells: V. Burkart, et al.; Biochem. Pharmacol. 48, 1379 (1994) Abstract
Fusidic acid in vitro activity: P. Collignon and J. Turnidge; Int. J. Antimicrob. Agents 12, S45 (1999), Review Abstract
Fusidic acid non-antibacterial activity: K. Christiansen; Int J Antimicrob Agents 12, S73 (1999), Review Abstract
Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus
: B.P. Howden & M.L. Grayson; Clin. Infect. Dis. 42, 394 (2006), Review Abstract

Further Categories Containing This Product:

Protein Synthesis Other Products

ALX-380-015

Revised 08-Oct-07

Mycophenolic acid
SYNONYMS	6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexanoic acid
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - Immunomodulators

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-015-M050		50 mg	30.00 USD
ALX-380-015-M250		250 mg	105.00 USD
ALX-380-015-G001		1 g	310.00 USD

Product Specification

FORMULA:	C₁₇H₂₀O₆
MW:	320.3
CAS NUMBER:	24280-93-1
MERCK INDEX:	14: 6327
SOURCE/HOST:	Isolated from Penicillium brevi-compactum.
PURITY:	≥98%
APPEARANCE:	White to off-white powder.
SOLUBILITY:	Soluble in methanol or methylene chloride; insoluble in water.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	+20°C
HAZARD:	TOXIC.

Product Description

Immunosuppressive agent that inhibits de novo purine nucleotide synthesis via inhibition of inosine-5’-monophosphate (IMP). Prevents the formation of xanthosine-5’-monophosphate (XMP) and guanosine-5’-monophosphate (GMP). Depletes tetrahydrobiopterin and decreases nitric oxide (NO) production by iNOS (NOS II) without affecting nNOS (NOS I) activity. Suppresses cytokine-induced nitric oxide (NO) production in mouse and rat vascular endothelial cells.

Product Specific Literature References

Guanine nucleotide depletion and toxicity in mouse T lymphoma (S-49) cells: M.B. Cohen, et al.; J. Biol. Chem. 256, 8713 (1981) Abstract; Full Text
Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity: L.J. Langman, et al.; Clin. Chem. 41, 295 (1995) Abstract
Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells: M. Senda, et al.; Transplantation 60, 1143 (1995) Abstract
Mycophenolate mofetil and its mechanisms of action: A.C. Allison & E.M. Eugui; Immunopharmacology 47, 85 (2000) Abstract
Mycophenolic acid downregulates inducible nitric oxide synthase induction in astrocytes: D. Miljkovic, et al.; Glia 39, 247 (2002) Abstract
Mycophenolic acid inhibits inosine 5´-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages: C.A. Jonsson & H. Carlsten; Cell Immunol. 216, 93 (2002) Abstract
Inducible nitric oxide synthase inhibition by mycophenolic acid: D. Miljkovic, et al.; Mini Rev. Med. Chem. 4, 741 (2004), Review Abstract
Antifibrotic actions of mycophenolic acid: C. Morath, et al.; Clin. Transplant. 20, 25 (2006), Review Abstract

Further Categories Containing This Product:

Antibiotics - Nitric Oxide Pathway Modulators • Phenolic Acids

ALX-380-034

Revised 30-Jul-08

Concanamycin A
SYNONYMS	Folimycin
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - ATPase Inhibitors

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-034-C025		25 µg	55.00 USD
ALX-380-034-C100		100 µg	180.00 USD
ALX-380-034-M001		1 mg	750.00 USD

Product Specification

FORMULA:	C₄₆H₇₅NO₁₄
MW:	866.1
CAS NUMBER:	80890-47-7
RTECS:	CB9732000
SOURCE/HOST:	Isolated from Streptomyces sp.
PURITY:	≥96% (HPLC)
APPEARANCE:	White to off-white solid.
SOLUBILITY:	Soluble in methanol, DMSO or acetonitrile; insoluble in water.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
HANDLING:	Protect from light.
HAZARD:	VERY TOXIC.
IDENTITY:	Identity determined by ¹H-NMR.

Product Description

Antibiotic. More potent and specific H⁺-ATPase inhibitor than bafilomycin A₁(Prod. No. ALX-380-030). Inhibits acidification of organelles such as lysosomes and the Golgi apparatus. Blocks cell surface expression of viral glycoproteins without affecting their synthesis. Exhibits cytotoxic effects in a number of cell lines in a cell viability assay. Induces nitric oxide (NO) production.

Product Specific Literature References

Isolation and characterization of concanamycins A, B and C: H. Kinashi, et al.; J. Antibiot. (Tokyo) 37, 1333 (1984) Abstract
Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells: E.J. Bowman, et al.; PNAS 85, 7972 (1988) Abstract
Structure and function of vacuolar class of ATP-driven proton pumps: M. Forgac; Physiol. Rev. 69, 765 (1989) Abstract
Intravesicular acidification correlates with binding of ADP- ribosylation factor to microsomal membranes: S. Zeuzem, et al.; PNAS 89, 6619 (1992) Abstract
Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases: S. Drose, et al.; Biochemistry 32, 3902 (1993) Abstract
Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus: M. Muroi, et al.; Cell Struct. Funct. 18, 139 (1993) Abstract
Folimycin (concanamycin A), an inhibitor of V-type H(+)-ATPase, blocks cell-surface expression of virus-envelope glycoproteins: M. Muroi, et al.; BBRC 193, 999 (1993) Abstract
Purification of vacuolar ATPase with bafilomycin C1 affinity chromatography: T.J. Rautiala, et al.; BBRC 194, 50 (1993) Abstract
Involvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells: M. Yilla, et al.; J. Biol. Chem. 268, 19092 (1993) Abstract; Full Text
Specific inhibitors of vacuolar type H(+)-ATPases induce apoptotic cell death: T. Nishihara, et al.; BBRC 212, 255 (1995) Abstract
Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells: F.J. Sharom, et al.; Biochem. J. 308 (Pt2), 381 (1995) Abstract
Concanamycin A, the specific inhibitor of V-ATPases, binds to the V(o) subunit c: M. Huss, et al.; J. Biol. Chem. 277, 40544 (2002) Abstract
Organization of the biosynthetic gene cluster for the macrolide concanamycin A in Streptomyces neyagawaensis ATCC 27449: S.F. Haydock, et al.; Microbiology 151, 3161 (2005) Abstract; Full Text
Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells: J. Hong, et al.; J. Pharmacol. Exp. Ther. 319, 672 (2006) Abstract

Related Products

ALX-380-030

Bafilomycin A₁

Further Categories Containing This Product:

Antibiotics - Nitric Oxide Pathway Modulators • H+-ATPase / Related Products • Antitumor Antibiotics

ALX-380-092

Revised 03-Jul-08

Radicicol
SYNONYMS	Monorden 1aS-(1aR,2Z,4E,14,15aR*)]-8-Chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-6H-oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - Antifungal

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-092-M001		1 mg	75.00 USD
ALX-380-092-M005		5 mg	295.00 USD

Product Specification

FORMULA:	C₁₈H₁₇ClO₆
MW:	364.8
CAS NUMBER:	12772-57-5
MERCK INDEX:	14: 6253
RTECS:	RR1105000
SOURCE/HOST:	Isolated from Humicola fuscoatra.
PURITY:	≥98% (HPLC)
APPEARANCE:	White to light yellow powder.
SOLUBILITY:	Soluble in DMSO, methanol or acetone.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
HANDLING:	Protect from light.
HAZARD:	MAY BE CARCINOGENIC. HARMFUL.

Product Description

Antifungal macrocyclic lactone antibiotic with antimalarial activity. Potent inhibitor of HSP90. Binds more strongly to HSP90 (nanomolar affinity) than to Grp94. Also binds to yeast HSP90, E. coli HtpG and TRAP-1. Non-competitive inhibitor of ATP citrate lyase. Anti-angiogenic. Specifically inhibits the interaction between HIF-1α/Arnt heterodimer and the hypoxia-responsive element (HRE), reducing VEGF expression. Protein tyrosine kinase inhibitor, e.g. p60^v-src(IC₅₀=0.27nM). Inhibitor of cyclooxygenase-2 (COX-2) expression (IC₅₀=27nM) without affecting COX-1 expression in LPS-stimulated macrophages. Induces the differentiation of HL-60 cells into macrophages, blocking cell cycle at G1 and G2. Suppressor of NIH 3T3 cell transformation by diverse oncogenes such as mos, ras and src in part by blocking the key signal transduction intermediates such as MAP kinase and GAP-associated p62. Inhibitor of AP-1-, NF-κB- and serum response factor (SRF)-mediated transcription (e.g. expression of iNOS). Represses the transcriptional function of the estrogen receptor. Inhibits archeal growth and DNA topoisomerase VI (a Topo IIB family topoisomerase). Blocks replication of negative-strand RNA viruses.

Product Specific Literature References

Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol: H.J. Kwon, et al.; Cancer Res. 52, 6926 (1992) Abstract
Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis: T. Oikawa, et al.; Eur. J. Pharmacol. 241, 221 (1993) Abstract
Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis: P. Chanmugam, et al.; J. Biol. Chem. 270, 5418 (1995) Abstract; Full Text
Suppression of RAS and MOS transformation by radicicol: J.F. Zhao, et al.; Oncogene 11, 161 (1995) Abstract
Induction of differentiation of HL-60 cells by the anti-fungal antibiotic, radicicol: Y. Shimada, et al.; J. Antibiot. 48, 824 (1995) Abstract
Radicicol inhibits tyrosine phosphorylation of the mitotic Src substrate Sam68 and retards subsequent exit from mitosis of Src-transformed cells: I. Pillay, et al.; Cell Growth Differ. 7, 1487 (1996) Abstract
Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway: S. Soga, et al.; J. Biol. Chem. 273, 822 (1998) Abstract; Full Text
Antimalarial activity of radicicol, heptelidic acid and other fungal metabolites: Y. Tanaka, et al.; J. Antibiot. 51, 153 (1998) Abstract
Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol: S.V. Sharma, et al.; Oncogene 16, 2369 (1998) Abstract
Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin: S.M. Roe, et al.; J. Med. Chem. 42, 260 (1999) Abstract
T.W. Schulte, et al.; Mol. Endocrinol. 13, 1435 (1999) Abstract; Full Text
Radicicol suppresses expression of inducible nitric-oxide synthase by blocking p38 kinase and nuclear factor-kappaB/Rel in lipopolysaccharide-stimulated macrophages: Y.J. Jeon, et al.; J. Pharmacol. Exp. Ther. 294, 548 (2000) Abstract; Full Text
Radicicol binds and inhibits mammalian ATP citrate lyase: S.W. Ki, et al.; J. Biol. Chem. 275, 39231 (2000) Abstract; Full Text
Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade: P.N. Kim, et al.; Cell Growth Differ. 12, 543 (2001) Abstract; Full Text
Radicicol-sensitive peptide binding to the N-terminal portion of GRP94: S. Vogen, et al.; J. Biol. Chem. 277, 40742 (2002) Abstract; Full Text
Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol: E. Hur, et al.; Mol. Pharmacol. 62, 975 (2002) Abstract; Full Text
Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90: M.O. Lee, et al.; Mol. Cell Endocrinol. 188, 47 (2002) Abstract
Development of radicicol analogues: S. Soga, et al.; Curr. Cancer Drug Targets 3, 359 (2003) Abstract
Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor: K. Harashima, et al.; Int. J. Radiat. Biol. 81, 63 (2005) Abstract
Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol: D. Gadelle, et al.; Nucleic Acid Res. 33, 2310 (2005) Abstract
Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site: M.K. Hadden, et al.; Curr. Top. Med. Chem. 6, 1173 (2006), Review Abstract
The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?: C.R. Barker, et al.; Int. J. Cancer 118, 2685 (2006) Abstract
Structural basis for topoisomerase VI inhibition by the anti-Hsp90 drug radicicol: K.D. Corbett & J.M. Berger; Nucleic Acids Res. 34, 4269 (2006) Abstract
Chemistry and biology of resorcylic acid lactones: N. Winssinger & S. Barluenga; Chem. Commun. (Camb.) 22 (2007) Abstract
Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses: J.H. Connor, et al.; Virology 362, 109 (2007) Abstract

Further Categories Containing This Product:

Tyrosine Kinase Inhibitors • Cell Cycle Blockers & Inhibitors / Related Products • Estrogen & Estrogen Receptors / Related Products • Antibiotics - Nitric Oxide Pathway Modulators • Antitumor Agents (Hormone-related) • NF-kB Pathway Inhibitors • Malaria / Related Products • Antibiotics - Antimalarial • Antibiotics - Protein Kinase Inhibitors • Antibiotics - NF-kB Inhibitors • Antibiotics for Angiogenesis Research • Antibiotics for Cell Cycle Research • HSP90 / HtpG / Related Products • Antibiotics - Topoisomerase Inhibitors • RNA Polymerases / Related Products

ALX-380-109

Revised 01-Jul-08

Minocycline . hydrochloride